Biomarkers are measurable indicators of biological processes, health, or disease. Just as cholesterol markers inform cardiovascular risk assessment, brain biomarkers such as pTau217, pTau181, NfL, pTau217/Aβ42 ratio, and GFAP contribute to a more complete picture of neurobiological change. Historically, these biomarkers were accessible primarily through invasive spinal taps or costly neuroimaging. Recent advances now allow for high-sensitivity blood-based measurement, enabling broader clinical access with comparable biological relevance.
AlzLabs' blood biomarker approach is not diagnostic nor does it intend to predict individual outcomes. Instead, our approach provides objective, biologically-grounded insights into underlying neurodegenerative processes, which can begin years to decades before overt cognitive symptoms. These insights support earlier risk stratification, monitoring, and informed clinical decision-making, including lifestyle considerations.
Analytical rigor is central to everything we do. For certain complex blood tests, we run samples in “technical duplicates”—meaning we perform the same test twice and check that the results closely agree. This helps confirm precision and ensures the reported value is consistent.
Brain biomarker data is designed to support clinical use beyond a single data point. Longitudinal tracking from baselines makes it possible to monitor biological changes over time, helping clinicians to contextualize results, assess trends, and guide evidence-informed recommendations as part of a comprehensive brain health strategy.